Biotech and Pharmaceuticals
Moderna says FDA delayed RSV vaccine approval to end of May
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end of May due to “administrative constraints” at the agency. The FDA was expected to make a decision on the RSV shot on Sunday. The agency […]
Read MoreNovavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company’s Covid […]
Read MoreAstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand
In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images) Nurphoto | Nurphoto | Getty Images Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. The so-called Vaxzevria vaccine was developed […]
Read MoreHealthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! A highly popular group of weight loss and diabetes drugs is still hard […]
Read MoreAmgen, newer rivals could threaten Novo Nordisk and Eli Lilly’s weight loss drug dominance
The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival. Amgen […]
Read MoreGenerative AI will be coming up with new prescription drugs all on its own in the around long run
Eli Lilly chief information and facts and digital officer Diogo Rau was recently concerned in some experiments in the business office, but not the common drug study work that you could assume to be amid the lab tinkering inside a main pharmaceutical business. Lilly has been utilizing generative AI to lookup as a result of […]
Read MoreAmgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Pavlo Gonchar | Lightrocket | Getty Images Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, […]
Read MoreWegovy maker Novo Nordisk down 4%, heads for worst day considering the fact that Oct
Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% decline on Thursday as analysts pored about the facts of the firm’s first-quarter final results and monitored a opportunity rival body weight reduction procedure. It puts the stock on observe for its sharpest everyday drop considering the fact that Oct 2023, in accordance to […]
Read MoreAmgen scraps experimental weight loss pill, moves forward with injection
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. The announcement is a setback for […]
Read MoreModerna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company’s cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The results come as Moderna inches closer to putting another product on the market, which it badly […]
Read More